Rockwell Medical Q2 net sales $25.8M (+43% YoY), net income $0.3M, raises FY 2024 guidance

ROCKWELL MEDICAL, INC.

2024-Q2 EPS reported -$0.05 revenue$48,508,000

Net sales $25.8M (+43% YoY); gross profit $4.6M (+341%); gross margin expanded to 18% from 6%.
Net income $0.3M vs net loss of $3.3M in Q2 2023; adjusted EBITDA $1.5M vs negative $2.3M.
Generated $1.4M in cash flow from operations; cash and equivalents rose to $11.9M from $8.6M.
FY 2024 net product sales guidance raised to $95M–$98M (from $90M–$94M) and Adjusted EBITDA to $0.75M–$1.5M.
Promoted Tim Chole to Chief Commercial Officer; amended Evoqua asset purchase agreement for extended payment terms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.